Literature DB >> 14600829

Identification of transcripts from a subtraction library which might be responsible for the mild phenotype in an intrafamilially variable course of Duchenne muscular dystrophy.

Marco Sifringer1, Birgit Uhlenberg, Stefanie Lammel, Rita Hanke, Benjamin Neumann, Arpad von Moers, Ina Koch, Astrid Speer.   

Abstract

While frame-shift mutations are usually found in Duchenne muscular dystrophy (DMD), in-frame mutations are associated with the less severe phenotype of Becker's muscular dystrophy. Exceptions have been reported in both directions suggesting the existence of modifying genes, which might be helpful for innovation of new therapeutic strategies. We report on the very rare case of an intrafamilially different course of DMD, with the younger brother being far less affected than the older one when compared at the same age. In this context, we constructed a subtraction library enriched for transcripts over-expressed in the patient with the milder phenotype. Twelve random clones were sequenced, followed by database analysis. Six of them, casein kinase 1 alpha 1, RAP2B, dynactin 3 light chain, core binding factor beta, myosin light polypeptide 2 and one hypothetical gene, were further analysed by real-time RT-PCR. All these genes were over-expressed 3-20 times in the less affected patient compared with the more severely affected one. Casein kinase 1 and the hypothetical gene showed even a slightly higher expression than the control. Up-regulation of myosin light polypeptide 2, one of the most sensitive markers of muscle fibre regeneration, obviously reflects the milder phenotype. Casein kinase 1, dynactin and core binding factor are supposed to be involved in cell cycle pathways. RAP is a component of the signalling network which controls fundamental cellular processes such as proliferation and differentiation. All four might be interesting candidates for a therapeutic approach to diminish progression of dystrophy in DMD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600829     DOI: 10.1007/s00439-003-1041-2

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  24 in total

1.  In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide.

Authors:  R J Bartlett; S Stockinger; M M Denis; W T Bartlett; L Inverardi; T T Le; N thi Man; G E Morris; D J Bogan; J Metcalf-Bogan; J N Kornegay
Journal:  Nat Biotechnol       Date:  2000-06       Impact factor: 54.908

2.  Prestin is the motor protein of cochlear outer hair cells.

Authors:  J Zheng; W Shen; D Z He; K B Long; L D Madison; P Dallos
Journal:  Nature       Date:  2000-05-11       Impact factor: 49.962

3.  Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle.

Authors:  Judith N Haslett; Despina Sanoudou; Alvin T Kho; Richard R Bennett; Steven A Greenberg; Isaac S Kohane; Alan H Beggs; Louis M Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

4.  Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy.

Authors:  X Xiao; J Li; Y P Tsao; D Dressman; E P Hoffman; J F Watchko
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

5.  Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides.

Authors:  T A Rando; M H Disatnik; L Z Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Elevated p21 mRNA level in skeletal muscle of DMD patients and mdx mice indicates either an exhausted satellite cell pool or a higher p21 expression in dystrophin-deficient cells per se.

Authors:  S Endesfelder; A Krahn; K A Kreuzer; U Lass; C A Schmidt; C Jahrmarkt; A von Moers; A Speer
Journal:  J Mol Med (Berl)       Date:  2000       Impact factor: 4.599

Review 7.  Molecular pathophysiology and targeted therapeutics for muscular dystrophy.

Authors:  E P Hoffman; D Dressman
Journal:  Trends Pharmacol Sci       Date:  2001-09       Impact factor: 14.819

8.  Non-isotopic analysis of single strand conformation polymorphism (SSCP) in the exon 13 region of the human dystrophin gene.

Authors:  U Lenk; R Hanke; U Kräft; K Grade; I Grunewald; A Speer
Journal:  J Med Genet       Date:  1993-11       Impact factor: 6.318

9.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

10.  Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse.

Authors:  C J Mann; K Honeyman; A J Cheng; T Ly; F Lloyd; S Fletcher; J E Morgan; T A Partridge; S D Wilton
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  9 in total

1.  Cardiac and pulmonary function variability in Duchenne/Becker muscular dystrophy: an initial report.

Authors:  David J Birnkrant; Mahi Lakshmi Ashwath; Garey H Noritz; Michelle C Merrill; Tushar A Shah; Carol A Crowe; Robert C Bahler
Journal:  J Child Neurol       Date:  2010-05-25       Impact factor: 1.987

2.  Magnetic Resonance Monitoring of Disease Progression in mdx Mice on Different Genetic Backgrounds.

Authors:  Ravneet Vohra; Abhinandan Batra; Sean C Forbes; Krista Vandenborne; Glenn A Walter
Journal:  Am J Pathol       Date:  2017-09       Impact factor: 4.307

3.  Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.

Authors:  Stefanie Endesfelder; Alexander Kliche; Hanns Lochmüller; Arpad von Moers; Astrid Speer
Journal:  J Mol Med (Berl)       Date:  2004-11-05       Impact factor: 4.599

4.  NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth.

Authors:  Andrzej Stepulak; Marco Sifringer; Wojciech Rzeski; Stefanie Endesfelder; Alexander Gratopp; Elena E Pohl; Petra Bittigau; Ursula Felderhoff-Mueser; Angela M Kaindl; Christoph Bührer; Henrik H Hansen; Marta Stryjecka-Zimmer; Lechoslaw Turski; Chrysanthy Ikonomidou
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

5.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

6.  Left ventricular dysfunction in duchenne muscular dystrophy and genotype.

Authors:  Mahi L Ashwath; Irwin B Jacobs; Carol A Crowe; Ravi C Ashwath; Dennis M Super; Robert C Bahler
Journal:  Am J Cardiol       Date:  2014-05-02       Impact factor: 2.778

7.  Sibling concordance for clinical features of Duchenne and Becker muscular dystrophies.

Authors:  Sydney Pettygrove; Zhenqiang Lu; Jennifer G Andrews; F John Meaney; Daniel W Sheehan; Elinora T Price; Deborah J Fox; Shree Pandya; Lijing Ouyang; Susan D Apkon; Zoe Powis; Christopher Cunniff
Journal:  Muscle Nerve       Date:  2014-06       Impact factor: 3.217

Review 8.  Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

Authors:  Joe W McGreevy; Chady H Hakim; Mark A McIntosh; Dongsheng Duan
Journal:  Dis Model Mech       Date:  2015-03       Impact factor: 5.758

9.  Two novel missense mutations in the myostatin gene identified in Japanese patients with Duchenne muscular dystrophy.

Authors:  Atsushi Nishiyama; Yasuhiro Takeshima; Kayoko Saiki; Akiko Narukage; Yoshinobu Oyazato; Mariko Yagi; Masafumi Matsuo
Journal:  BMC Med Genet       Date:  2007-04-12       Impact factor: 2.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.